Anesiva Inc

Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (November 2005)

49 slides from Anesiva's merger presentation, Nov 4, 2005

  1. Slide 1: Creating a Late-Stage Company Focused on Pain Management and Inflammation

    Creating a Late-Stage Company Focused on Pain Management and Inflammation November 4, 2005

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," " forecast," "anticipate," "intend," "pl

  3. Slide 3: Forward Looking Statements (2)

    FORWARD LOOKING STATEMENTS (2) Additional Information and Where to Find It Corgentech Inc. has filed a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. have filed a related joint proxy statement/prospectus, in connection with the merger transaction involving Corgen

  4. Slide 4: AlgoRx Pharmaceuticals, Inc. / Corgentech

    Algok @ Pharmaceuticals, Inc. CORGENTECH

  5. Slide 5: Creating a Late-Stage Company

    CREATING LATE-STAGE COMPANY Four product development programs focused on significant clinical problems with attractive market potential – Each drug has unique mechanism of action offering risk diversification – Each drug has potential for approval in multiple indications – Each drug can be commercia

  6. Slide 6: Prevalence of Pain in Seven Major Countries

    Above indications are all targets of Corgentech pipeline PATIENT NUMBERS PREVALANCE OF PAIN IN SEVEN MAJOR COUNTRIES Prevalence of post-operative pain 75,068,000 Prevalence of back pain 208,996,000 Prevalence of HIV and AIDS pain 847,000 Prevalence of diabetic neuropathy pain 13,243,000 Prevalence o

  7. Slide 7: Shortcomings of Current Treatments for Pain

    SHORTCOMINGS OF CURRENT TREATMENTS FOR PAIN Slow onset of action Insufficient efficacy Occurrence of side effects Need for frequent dosing Lack of site specificity Potential to cause physical dependence

  8. Slide 8: Product Pipeline

    ALGRX 3268 ALGRX 4975 * ALGRX 1207 * NF-kB Decoy * PRODUCT PIPELINE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Pre-procedural analgesia (003) Pre-procedural analgesia (004) Post-surgical pain Morton’s neuroma Tendonitis Cutaneous neuropathic pain Atopic dermatitis (eczema) * Does not reflect comprehensive

  9. Slide 9: Combined Company: Pain Management and Inflammation

    Pain Management and Inflammation COMBINED COMPANY Clear Regulatory Pathways Faster, Less Expensive Trials Substantial Body of Preclinical and Clinical Data Differentiated Products with Clear Advantages over Current Therapies Unmet or Underserved Medical Needs Sizable Patient Populations

  10. Slide 10: AlgoRx Pharmaceuticals, Inc. / Corgentech

    Algok @ Pharmaceuticals, Inc. CORGENTECH

  11. Slide 11: ALGRX 3268: Topical Local Anesthesia

    ALGRX 3268- TOPICAL LOCAL ANESTHESIA Key desirable product attributes – Sterile, pre-filled, needle-free disposable delivery system (Powderject ® ) – Rapid onset of action Within 1 minute with duration of about 10 minutes – No vasoconstriction with good dermal tolerability – Ease of use with no dres

  12. Slide 12: ALGRX 3268 Rapid Onset of Action vs EMLA

    ALGRX 3268 has an onset within one minute, whereas EMLA is labeled for a pretreatment period of at least one hour -30 -20 -10 Time after administration, minutes ALGRX 3268 Rapid Onset of Action Critical to Adoption of Product ALGRX 3268 Data from Phase 1 trial in 272 adults EMLA Package Insert for E

  13. Slide 13: ALGRX 3268 Development

    Protocol Age Group Phase Total Patients Primary Endpoint Status Antecubital Fossa Adults Safety and Efficacy Primary Endpoint Achieved Back of Hand Adults Safety and Efficacy Primary Endpoint Achieved Pharmacokinetics Adults Evaluate Circulating Lidocaine Primary Endpoint Achieved Antecubital Fossa

  14. Slide 14: Phase 3s: Pediatric Trials

    PHASE 3’s: PEDIATRIC TRIALS IDENTICAL PROTOCOLS Design – U.S. multicenter, randomized, double-blind, placebo-controlled Number of subjects – 500-600 subjects in each study Population – Pediatric subjects of either gender (ages 3-18) Objectives – Confirm efficacy, safety and tolerability of ALGRX 326

  15. Slide 15: First Phase 3 Results

    FIRST PHASE 3 RESULTS Primary endpoint achieved (p=0.007) – Statistically significantly less pain on needle insertion in treated group compared to placebo group assessed using FACES rating scale 574 patients at six U.S. clinical trial sites – ALGRX 3268 group = 289 patients (ages 3-18) – Placebo = 2

  16. Slide 16: Projected Timeline for ALGRX 3268

    PROJECTED TIMELINE FOR ALGRX 3268 Clinical – Data from second Phase 3 trial (004) expected by year’s end Regulatory – Reviewed as a drug by the FDA Analgesics and Acute Care Division Registration – File NDA in 2006 – Product approval in 2007

  17. Slide 17: Commercial Opportunities for ALGRX 3268

    COMMERCIAL OPPORTUNITIES FOR ALGRX 3268

  18. Slide 18: ALGRX 3268: Venipuncture Markets

    PROCEDURE NUMBERS Additional Target Market Includes the 66,000 Physician’s Offices, Clinical Labs and Blood Donation Centers in the U.S. ALGRX 3268: VENIPUNCTURE MARKETS Pediatric in-hospital procedures 18,000,000 Adult in-hospital emergency room visits 89,000,000 Hemodialysis patient visits 46,800,

  19. Slide 19: Pediatric In-Hospital Market

    PEDIATRIC IN-HOSPITAL MARKET Target market – Only 2.1MM out of 18MM venipuncture procedures in children’s hospitals and large academic institutions utilize a topical local anesthetic today Low utilization of topical local anesthetics ( 12% of pediatric procedures) due to: – slow onset of action – la

  20. Slide 20: ALGRX 3268 Drug Class Comparison

    EMLA ALGRX 3268 ALGRX 3268- DRUG CLASS COMPARISON 37% blanching, 30% erythema Minimal erythema Adverse Reactions 1-2 hours after removal 10-15 minutes Duration 60 minutes to several hours 1 minute Onset of Action Messy and requires covering Minimal Preparation Ease of Use +++ +++ Efficacy

  21. Slide 21: ALGRX 3268: Topical Local Anesthesia Market Dynamics

    Current market dynamics provide an excellent opportunity for a fast acting, easy to use topical local anesthetic product like ALGRX 3268 ALGRX 3268: TOPICAL LOCAL ANESTHESIA MARKET DYNAMICS Strong focus of pain management including treatment protocols and guidelines Increase in dedicated pediatric h

  22. Slide 22: ALGRX 3268: Potential Pediatric Market

    POTENTIAL SALES POTENTIAL ANNUAL PROCEDURES STRAWMAN UNIT PRICE Superior Product Profile + Promotional Efforts = Market Penetration and Market Growth ALGRX 3268: POTENTIAL PEDIATRIC MARKET $60mm - $80mm 5mm $12 - $16* $72mm - $96mm 6mm $12 - $16* $48mm - $64mm 4mm $12 - $16* $36mm - $48mm 3mm $12 -

  23. Slide 23: ALGRX 3268: Phased Marketing Approach

    ALGRX 3268: PHASED MARKETING APPROACH In-hospital Pediatric 18M

  24. Slide 24: AlgoRx Pharmaceuticals, Inc. / Corgentech

    Algok @ Pharmaceuticals, Inc. CORGENTECH

  25. Slide 25: ALGRX 4975 – VR1 Anesthetic: Capsaicin Overview

    Capsaicin Overview Blocks noxious pain with long duration ALGRX 4975 – VR1 ANESTHETIC Administered locally at the site of pain Single administration may provide analgesia for weeks to months Non-opioid based Only reduces long-term noxious pain associated with C-neurons Does not affect other nerve fi

  26. Slide 26: ALGRX 4975: Proof of Concept Established

    TARGET MARKETS MODEL FOR STUDY ALGRX 4975: PROOF OF CONCEPT ESTABLISHED Delay progression to surgery Musculoskeletal Pain Tendonitis / Osteoarthritis Complex Regional Pain Syndrome (CRPS) Local Neuropathic Pain Morton’s Neuroma Joint Replacement Post-Surgical Pain Bunionectomy

  27. Slide 27: ALGRX 4975 Development

    ALGRX 4975 DEVELOPMENT Protocol Phase Total Patients Primary Endpoint Status Postsurgical Pain Bunion Removal Surgery Time to Rescue Medication 72-hour Endpoint Achieved Bunion Removal Surgery Magnitude of Pain Relief 24 and 72- hour Endpoints Achieved Hernia Repair Magnitude and Duration of Pain Re

  28. Slide 28: Morton's Neuroma

    MORTON’S NEUROMA Type of localized post- trauma neuropathic pain Painful foot condition that typically occurs as a result of: – Running – Wearing high narrow shoes – Excessive standing Neuroma (thickened nerve tissue) – Forms as a result of injury to one of the nerves that leads to the toes – Leads

  29. Slide 29: Phase 2 Results: Morton's Neuroma

    PHASE 2 RESULTS: MORTON’S NEUROMA Objectives – Confirm efficacy, safety and tolerability of ALGRX 4975 vs. placebo administered by single injection into neuroma Design and population – U.S. randomized, double-blind, placebo-controlled – 58 subjects of either gender at two U.S. clinical trial sites A

  30. Slide 30: Commercial Opportunities for ALGRX 4975

    COMMERCIAL OPPORTUNITIES FOR ALGRX 4975

  31. Slide 31: ALGRX 4975: U.S. Post-Surgical and Neuropathic Pain Markets

    PROCEDURE NUMBERS ALGRX 4975: U.S. POST-SURGICAL AND NEUROPATHIC PAIN MARKETS POST-SURGICAL PAIN Bunionectomy 709,000 Cholecystectomy 1,230,000 Total knee replacement 412,000 Total hip replacement 346,000 Hernia repair 825,000 Hysterectomy 789,090 LOCAL NEUROPATHIC PAIN 1,269,000 TOTAL 5,580,090

  32. Slide 32: Post-Op Pain Drug Comparison

    Opioids ALGRX 4975 POST-OP PAIN DRUG COMPARISON Hours Weeks Duration Rapid Rapid Onset of action Respiratory depression, nausea, vomiting, ileus Cannot inject near large nerves Safety Frequent Single application Dosing +++ +++ Efficacy

  33. Slide 33: ALGRX 4975: Post-Operative Pain Market

    ALGRX 4975: POST-OPERATIVE PAIN MARKET U.S. post-operative pain market: $1.7 billion Virtually all patients experience some level of pain post operatively Pain in hospital associated with increased length of stay, longer recovery times, poorer patient outcomes

  34. Slide 34: Post-Trauma Neuropathic Pain: Background

    POST-TRAUMA NEUROPATHIC PAIN: BACKGROUND Approximately 1.2 million Americans suffer from a localized form of neuropathic pain resulting from trauma or surgery – Pain lasting months and often severe and debilitating Occurs following 10% of general and 30% of orthopedic surgeries – Most commonly assoc

  35. Slide 35: ALGRX 4975: Neuropathic Pain Market

    ALGRX 4975: NEUROPATHIC PAIN MARKET No drugs indicated for Morton’s neuroma or other post trauma neuropathic pain syndromes – Off label usage of Neurontin, Lidoderms, antidepressants and opioids U.S. neuropathic pain market: $1.9 billion Despite employing concomitant treatment with several drugs wit

  36. Slide 36: ALGRX 4975: Blockbuster Potential

    ALGRX 4975: BLOCKBUSTER POTENTIAL Significant unmet medical need Attractive product profile Large surgical volume Small target audience Specialized sales forces

  37. Slide 37: Avrina (NF-kB Decoy) for Eczema

    AVRINA™ (NF- k B DECOY) FOR ECZEMA

  38. Slide 38: Common, Chronic Problem

    COMMON, CHRONIC PROBLEM Eczema (Atopic Dermatitis) – Red, cracked, and unbearably itchy skin caused by excess inflammation in the skin – Makes the person more susceptible to infection 90% of people with AD have staph bacteria on their skin compared to <5% of people without AD – Affects about 15 mill

  39. Slide 39: Attractive Indication

    ATTRACTIVE INDICATION Unmet medical need – Existing therapies are not satisfactory (steroid and calcineurin inhibitors) – Safety issues with long-term application of steroids, especially in children, and black box warning for cancer risk on on calcineurin inhibitors Strong preclinical data showing e

  40. Slide 40: Lack of Rebound with NF-kB Decoy

    Stop Treatment LACK OF REBOUND WITH NF- B DECOY Start Daily Treatment Placebo NF- B Decoy Betamethasone Days

  41. Slide 41: Drug Comparison

    Steroids Calcineurin Inhibitors NF- B Decoy DRUG COMPARISON None Limits use None Skin-thinning ++ +++ +++ Onset of action Black box warning for cancer risk May cause significant side effects Limited Systemic exposure Frequent Once/twice a day Short-term +++ Occasional None Rebound Twice a day Short-

  42. Slide 42: Commercial Opportunity

    Total Dollars COMMERCIAL OPPORTUNITY $0 $100 $200 $300 $400 $500 $600 $700 $800 $900 Corticosteroids Protopic Elidel Focused Prescriber Base •10-20% of all dermatological visits •70% of all pediatric visits to a dermatologist Growing Market with new, premium priced drugs Family Practice 9% Internal

  43. Slide 43: AlgoRx Pharmaceuticals, Inc. / Corgentech

    Algok @ Pharmaceuticals, Inc. CORGENTECH

  44. Slide 44: ALGRX 1207

    ALGRX 1207 IND-enabling studies underway New chemical class of local anesthetic for topical analgesia Deep, rapid penetration of the skin and long duration of action Addresses a wide variety of procedures including: – Neuropathic pain – Dermatological surgery – Surgical incisions

  45. Slide 45: oS SS : ae : o . a Le i . : a e|seyysoue

    oS SS : ae : o . a Le i . : a e|seyysoue aje|dwioo jueoleq

  46. Slide 46: ALGRX 1207: Target Market

    Drug 2004 US Sales ($ in MM) Patient Cost/ Year OxyContin $1,500 $2,730 Neurontin $2,198 $2,430 Duragesic $1,266 $2,420 Lidoderm $309 $1,450 Drug 2004 US Sales ($ in MM) Patient Cost/ Year ALGRX 1207:TARGET MARKET OxyContin $1,500 $2,730 Neurontin $2,198 $2,430 Duragesic $1,266 $2,420 Lidoderm $309

  47. Slide 47: AlgoRx Pharmaceuticals, Inc. / Corgentech

    Algok @ Pharmaceuticals, Inc. CORGENTECH

  48. Slide 48: Delivering on Our Promises

    DELIVERING ON OUR PROMISES File IND for Phase 1 Trial of ALGRX 1207 for Pain Relief Report Clinical Data from Phase 1/2 Trial of Avrina™ (NF-kB Decoy) for Eczema Report Clinical Data from Second Phase 3 Trial of ALGRX 3268 Report Clinical Data from Phase 2 Trial of ALGRX 4975 for Morton’s Neuroma Re

  49. Slide 49: Thank You

    Thank you for joining us for today’s presentation. For additional information about the proposed merger of Corgentech and AlgoRx, please visit www.corgentech.com and the other sources described in our forward looking statement slide.

Algorx Pharmaceuticals — Merger or Acquisition (November 2005) on 6ix